AUTHORS
Davide Matino, MD, Erin Cockrell, DO2, Cedric Hermans, MD, PhD, MRCP3, Robert Klamroth, MD4, Ilgiz Rakhmatullin5, Amalie Roar Høgh6, Michele Schiavulli, MD7, Kingsley Hampton8, Cihan Ay Sr, MD9
AFFILIATIONS
1 McMaster University, Hamilton, Ontario, Canada
2 St Joseph's Hospital Center for Bleeding and Clotting Disorders,, Tampa, Florida, United States
3 Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium
4 University Hospital Bonn, Bonn, Germany, Vivantes Klinikum, Berlin, Friedrichshain, Germany
5 Novo Nordisk A/S, Søborg, Denmark
6 Novo Nordisk, Søborg, Denmark
7 Santobono Children’s Hospital, Napoli, Campania, Italy
8 University of Sheffield, Sheffield, United Kingdom
9 Medical University of Vienna, Vienna, Austria
ABSTRACT
Background
Denecimig (Mim8), a next-generation factor VIIIa mimetic, bridges FIXa and FX to restore thrombin generation, and has demonstrated a ≈15-fold greater potency versus clinical emicizumab ex vivo in hemophilia A (HA) patient plasma. Bleed protection has been demonstrated across denecimig’s phase 3 clinical trial program, with low annualized bleeding rate (ABR) and high proportions of patients with HA without or with FVIII inhibitors (HAwI) experiencing zero treated bleeds. FRONTIER5 (FR5; NCT05878938) established the safety of directly switching from emicizumab to denecimig without emicizumab washout or denecimig loading dose. Denecimig was well tolerated, with no safety concerns observed, and increased thrombin generation into the normal range, without evidence of an excessive response. These data report the clinical efficacy and safety of denecimig prophylaxis following switch from emicizumab and after transfer from FR5 into the FRONTIER4 (FR4; NCT05685238) open-label extension (OLE).
Methods
This post hoc analysis included participants in FR5, consisting of adults and adolescents aged ≥12 years with HA/HAwI, who previously received ≥8 weeks of emicizumab before enrolling into FR5. Patients chose denecimig prophylaxis once-every-week, once-every-2-weeks, or once-every-month using a tiered dosing approach. Patients then transferred into the FR4 OLE to continue denecimig prophylaxis. ABRs were evaluated during the following periods: (1) historical emicizumab treatment prior to FR5, using a negative binomial regression model with the logarithm of treatment duration as an offset, (2) the 26-week FR5 treatment period, and (3) the FR4 OLE follow-up (0–26 weeks and 26–52 weeks). ABRs for periods 2 and 3 were estimated using a negative binomial regression model with the logarithm of treatment duration as an offset and inhibitor status included as a factor using a treatment-policy approach and included only treated spontaneous and traumatic bleeds (surgical bleeds were excluded). Individual ABRs and the proportions of participants experiencing zero treated bleeds were summarized descriptively.
Results
Patient demographics and baseline characteristics for FR5 have been previously reported. Overall, 61 participants were included in the historical emicizumab and first 6 months of denecimig analyses in FR5; 60 participants contributed data during the >6–12-month denecimig interval, and 57 participants contributed data during the >12–18-month interval in FR4 OLE. During historical emicizumab treatment, estimated ABR was 2.06 (95% confidence interval [CI] 1.23–3.43) over the analysis period (mean 0.99 years; range 9.1–104.7 weeks); 126 treated bleeds were reported in 28/61 (45.9%) participants, and 33/61 (54.1%) participants were reported to have zero treated bleeds. After a direct switch to denecimig in FR5 (mean treatment analysis period: 0.50 years), estimated ABR was 1.21 (95% CI 0.68–2.15); 40 treated bleeds were reported in 17/61 (27.9%) participants and 44/61 (72.1%) had zero treated bleeds. During the subsequent >6–12-month and >12–18-month periods of FR4 OLE, estimated ABR (95% CI) was 1.38 (0.69–2.74) and 1.26 (0.65–2.47), respectively. Treated bleeds occurred in 15/60 (25.0%) and 14/57 (24.6%) participants, accounting for 39 and 36 treated bleeds, respectively, while 45/60 (75.0%) and 43/57 (75.4%) participants had zero treated bleeds. In alignment with ABR results, thrombin generation assessed by thrombin peak height increased into the normal reference range and was sustained throughout the >6–12-month and >12–18-month periods of FR4 OLE. An adverse event rate of 3.48 per patient-year of exposure (PYE) with 43 patients experiencing 107 events, and 3.01 per PYE with 45 patients experiencing 242 events occurred in FR5 and FR4 OLE, respectively. No thromboembolic events were reported. One hypersensitivity reaction was reported and assessed to be unlikely related to denecimig.
Conclusions
Following a direct switch from emicizumab to denecimig, adolescents and adults with HA/HAwI experienced low treated bleed rates and a high proportion of zero treated bleeds throughout FR5, which was sustained during the FR4 OLE study. Thrombin generation increased into the normal reference range with denecimig and was sustained in FR4 OLE. No new safety signals with denecimig were observed.
DISCLOSURES
Davide Matino, MD: Pfizer - Honoraria; Sanofi - Honoraria; Novo Nordisk - Honoraria; Roche - Honoraria; Sobi - Honoraria; Octapharma - Honoraria; Sanofi - Research Funding; Pfizer - Research Funding; Roche - Research Funding; Pfizer - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony)